February 19, 2026 is the publication date context for a regulatory update on a CPAP therapy feature that tests a min max recommender tool in obstructive sleep apnea. The study compares CPAP with the min max recommender tool to CPAP with default settings. The sponsor is ResMed and the trial is not yet recruiting. Regulators, device makers and clinical teams will want to monitor this activity as part of ongoing device development, risk management and post market surveillance planning. Meta description: A regulatory update on a CPAP therapy feature testing a min max recommender tool for obstructive sleep apnea and its potential implications for device safety and performance.
What changed in CPAP therapy research with a min max recommender tool?
The protocol introduces a CPAP device configuration that uses a min max recommender tool as the intervention. This is compared with CPAP using default settings as the comparator. The condition studied is obstructive sleep apnea. The sponsor is ResMed. The trial status is not yet recruiting and the record is listed on ClinicalTrials.gov with identifier NCT07400861. This article reports the trial design and the regulatory context without asserting outcomes.
What device features are tested?
The intervention centers on a CPAP device configured with a min max recommender tool meant to guide therapy pressure within defined bounds. The goal is to support consistent device delivery and adherence while maintaining a clear safety profile. The comparator relies on standard CPAP settings and conventional device functions. The primary objective is to describe the design and planned population and to outline safety and performance expectations for the new configuration. The statements here reflect the trial protocol and do not reflect results.
Who is the population?
The source text notes obstructive sleep apnea as the condition studied. It does not specify age or comorbidity details within the record. Regulators and sponsors will consider such information during protocol review as part of risk assessment and informed consent considerations.
Why this matters to patients and regulators?
The addition of a min max recommender tool has the potential to influence how CPAP therapy is delivered and how treatment parameters are set. If the tool affects exposure controls or safety margins, it could influence the overall safety profile and the planning for post market surveillance. Regulators expect explicit documentation of the intended purpose, performance characteristics and safety considerations for any new device configuration. The record signals a disciplined approach to device improvement by the sponsor and offers stakeholders a window into ongoing regulatory compliance planning.
What are the regulatory implications?
Registering the trial on ClinicalTrials.gov demonstrates transparency about the testing plan for a device feature. The status Not yet recruiting indicates enrollment has not begun. The sponsor, ResMed, is accountable for the protocol and for safety monitoring. For MDR compliance, an automated recommender feature requires a defined intended purpose, performance attributes and risk controls to be documented in the device technical documentation. This article relies on the trial record for factual context and cautions readers that outcomes and safety conclusions are not yet reported.
Trial details and sponsor context
Obstructive sleep apnea is the condition described in the study. The interventions are CPAP with min max recommender tool and CPAP with default settings. The sponsor is ResMed. The status is not yet recruiting. The clinical trial is listed on ClinicalTrials.gov with identifier NCT07400861 and a page accessible through the source link.
- 1. When will enrollment begin?
Enrollment has not started yet according to the current record. - 2. Who is sponsoring this trial?
The sponsor listed is ResMed. - 3. What condition is being studied?
Obstructive sleep apnea is the condition described in the trial. - 4. Where can I find more information?
ClinicalTrials.gov page for NCT07400861 is provided in the source text.
Conclusion and implications
This trial represents a focused effort to incorporate a min max recommender tool into CPAP therapy for obstructive sleep apnea. Regulators will look for clear documentation of intended use, performance and safety. Clinicians and device stakeholders should monitor the trial status and any updates from the sponsor and the registry. The absence of results at this stage means no conclusions about safety or efficacy can be drawn from this record alone.
Disclaimer for professionals
This article is intended for a professional audience and is not legal advice. It summarizes a trial record and regulatory considerations without providing definitive claims about device safety or performance.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07400861?term=medical+device